Amgen
Company
|
ImmunoGen licenses technology to Amgen for $1M...totaling $34 million plus royalties on the sales of any resulting products. In September, Amgen licensed rights to the same technology for a different target. Both the prior and current licensing deals are for undisclosed cancer targets. In this article: Amgen Inc., Cancer, and Massachusetts |
-
Centre Daily Times | 7 days ago
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company’s TAP Technology
...in September 2009. "Amgen undertook extensive diligence prior to taking the first license that enabled them to move ahead quickly with this second license," commented Daniel Junius, President and Chief Executive Officer. "The commitment...
In this article: Amgen Inc., Cancer, Genentech, Safe harbor, Fiscal year, Private Securities Litigation Reform Act of 1995, and Monoclonal antibodies
-
Medical News Today | November 06, 2009
Amgen Announces Overall Survival Results For Vectibix(R) In First-Line Metastatic Colorectal Cancer
Amgen Announces Overall Survival Results For Vectibix(R) In First-Line Metastatic Colorectal Cancer Article Date: 06 Nov 2009 - 2:00 PST Amgen (Nasdaq: AMGN) announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab)...
In this article: Panitumumab, Cancer, KRAS, Oxaliplatin, Chemotherapy regimens, U.S. Food and Drug Administration, Medical advice, Hypotension, and Irinotecan
-
PR Newswire: Health / Biotech | 3 days ago
Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
...arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and...
In this article: Thrombocytopenia, Denosumab, Cancer, European Union, FDA, Breast cancer, United States, Corticosteroid, and Rheumatoid arthritis
-
www.breakawayfromcancer.com
Breakaway from Cancer
Amgen is expanding the reach of its Breakaway from Cancer® initiative through ... In addition, Amgen and Breakaway from Cancer have joined forces with the Lance ...
-
www.fiercebiotech.com
Safety fears derail late-stage Amgen cancer trial - FierceBiotech
Amgen has been dealt a serious blow to its hopes to develop new cancer therapies. ... Amgen's denosumab prevents fractures in big cancer study ...
-
www.xconomy.com
Amgen Cancer Drug Getting Personal, Which May Be a Good Thing ...
Amgen is preparing to make an unusual argument to an FDA advisory panel tomorrow. ... Amgen's Bid to Make Cancer Drug "Personalized" Lacks Data, FDA Panel Says ...
-
www.amgentourofcalifornia.com
about amgen | Amgen Tour of California
... from Cancer™ is a complementary component to the Amgen race sponsorship. ... Amgen's Breakaway from Cancer nonprofit partners play leading roles in every ...
-
www.drugstorenews.com
Amgen's cancer drug fails to increase overall survival rate ...
FDA rejects colorectal cancer treatment. Amgen, GSK, Novartis win top drug industry award ... Investigational cancer treatment yields favorable results, Amgen says ...
-
Amgen Shows Off Cancer Drug Pipeline Before Scientific ...
Amgen became the world's biggest biotech company because of its ability to treat the side effects of cancer chemotherapy. But Amgen's dream over the past decade
Trends
Loading...
More on Amgen
Description from Wikipedia:
Amgen Inc. (NASDAQ: AMGN, SEHK: 4332) is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the largest independent biotech firm. The company employs approximately 14,000 staff members including the 125 Allied-Barton Security staff and A-post personnel in 2007. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
BusinessWeek ranked Amgen fourth on the S&P 500 for being the most "future-oriented" of those five hundred corporations. BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000.
Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County. Amgen is also a member of the Pennsylvania Bio commerce organization.
With plans to expand into a new campus under construction in South San Francisco, Amgen abruptly halted construction on the plans and instead put the 365000 sqft of new space on the sublease market.
In 2006, Amgen began sponsoring the Tour of California, one of only three major Union Cycliste Internationale events in the United States.
- Name:
- Amgen Incoprporativo.
- Type:
- Public (NASDAQ: AMGN)
- Location:
- Thousand Oaks, California
- Founded:
- 1980
- Stock Symbol (NASDAQ):
- AMGN
- Industry:
- Biotechnology
- Key People:
- Kevin W. Sharer, President & CEO
- Products:
- Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, and Sensipar / Mimpara
- Revenue:
- $14.771 Billion USD (2007)
- Net Income:
- $3.166 Billion USD (2007)
- No. of Employees:
- 17,500 (2007)
- Market Cap:
- $53 Billion USD
Explore everything named Amgen...
